FDA announces updated schedule for the June meetings regarding five pivotal vaccine decisions
Who needs data when you’ve got regulatory capture?
By Toby Rogers | May 29, 2022
I. The June FDA meetings
This week the Washington Post copied and pasted from a Pfizer press release to announce yet another scientific miracle(TM) that will completely fail in practice. In the process WaPo also got some quotes from the FDA who have now nailed down the schedule for the 4 meetings in June in which they intend to assemble the final pieces for Pharma’s permanent dominance over the American people.
The new schedule is as follows:
June 7, Novavax
June 14, Moderna in kids 6 to 17 years old
June 15, Moderna in kids 6 months to 5 years AND Pfizer in kids 6 months to 4 years
June 28, “Future Framework” (the plan to skip clinical trials in perpetuity)
There is a lot to parse in the WaPo’s brief article.
Contrary to the breathless headline, they still don’t have any data.
Pfizer and BioNTech said the 80 percent efficacy finding was preliminary and based on 10 cases of Covid-19 in the study population as of the end of April. Once 21 cases have occurred, the companies will conduct a more formal analysis of efficacy… Pfizer and BioNTech said they plan to finish filing data with the FDA this week — and warned that the efficacy number was fluid because results are still arriving.
Let’s recap how we got here:
🚩 The Pfizer clinical trial in kids under 5 failed in December 2021.
🚩 So Pfizer added a third dose and that trial also apparently failed in February (which is why Pfizer was forced to withdraw its application on February 10).
🚩 Now Pfizer is describing a jerry-rigged trial of a third dose in 1,678 kids ages 6 months to four years old. Pfizer did not disclose how the kids were divided between the treatment and control group so it is impossible to run our own calculations on efficacy. Out of that sample, 10 developed Covid — although it is not clear how the 10 were distributed between the treatment and control group. (I suppose some quant on Twitter will figure out how to work backwards from Pfizer’s claims to calculate the numbers in each of these categories but needless to say, this is not the proper way to do science.) Of course Pfizer also failed to describe the contents of the “placebo.”
How exactly will Pfizer double the number of Covid-19 cases in the clinical trial in the next month given that 74.2% of kids already had natural immunity in February which means that nearly 100% of children likely have natural immunity by now?
Also, is the FDA seriously considering basing national policy, that impacts 18 million children, by relying a study with only 10 cases? It appears that the FDA is not even pretending to care about science anymore.
What little data they have will be based on antibodies in the blood, not health outcomes in the real world. That’s strange because the members of the FDA’s Vaccines and Related Biological Products Advisory Committee unanimously acknowledged on April 6 that there are “no correlates of protection” in connection with Covid-19 shots (this means that there are no valid proxy measures, such as antibody counts, that can determine whether someone who has received this shot is immune to the virus or not.)
WaPo continues:
While the adult trials recruited tens of thousands of volunteers and waited to see if vaccinated people were better protected, the children’s vaccine trials were primarily designed to measure immune responses using blood tests.
No they were not “primarily designed to measure immune responses using blood tests.” The studies were intentionally undersized to hide harms from the shots in addition to other tricks that they use to skew the results (such as kicking you out of the trial if you call 911 or go the the emergency room). But when one shrinks the sample size, surprise! it becomes impossible to detect actual health benefits from the shots (the signal would have been tiny if at all, but when one uses a sample that small then any positive signal can also disappear into statistical insignificance.)
II. The bigger picture
Tony Fauci and the NIAID funded the creation of a chimera virus that escaped a bioweapons lab and killed 6.3 million people worldwide.
Public health authorities have blocked access to safe and effective prophylaxis and early treatment throughout the pandemic in order to create the market for Covid-19 vaccines.
Covid-19 shots skipped essential safety steps (e.g. challenge trials in animals) and were rushed to market with no long term data.
In practice the mRNA shots suppress immune function for 6 weeks after the first shot, provide about two months worth of protection against coronavirus, then efficacy wanes quickly and becomes negative after six months. Meanwhile, these shots cause more side effects than any vaccine ever invented.
Popular support for the current regime has collapsed. More people have died of Covid under Mr. I Believe the Science(TM) than under Orange Man Bad. Only hypochondriacs in blue states seek out additional doses. Meanwhile Sudden Adult Death Syndrome stalks the true believers. In the past 48 hours alone actor Ray Liotta, Andy Fletcher of Depeche Mode, British drummer Alan White (from the band YES), and comedian Phil Butler were all likely killed by Covid-19 shots. It’s impossible to hide all of the bodies at this point.
The FDA seems to know that their window is closing to implement the Final Solution. So they are rushing to put the finishing touches on their plans to inject this toxic junk into the littlest kids in America. The FDA knows that these shots cannot pass proper regulatory review so they’ve developed a plan to rig the process in favor of Pharma in perpetuity. On June 28, the FDA’s “expert advisory committee” will vote on a “Future Framework” whereby all future (reformulated) Covid-19 shots will automatically be deemed “safe and effective(TM)” without any additional clinical trials, on the theory that they are “biologically similar” to existing Covid-19 shots.
What this means is that by fall, the Covid-19 shots that they will be injecting into Americans of all ages will have a new formula that skipped clinical trials altogether.
Injecting people with genetically modified mRNA that skipped clinical trials is genocide. It’s slower than the Nazi Final Solution. But it’s genocide all the same. Indeed the slower pace of the FDA Final Solution (5% to 15% increase in all cause mortality every year) might be even more lethal in the long run. It’s sinister in that they are intentionally building in plausible deniability (‘the FDA said it was safe’) to help the medical establishment feel virtuous while participating in genocide.
I’ll just conclude by saying: be careful what you wish for FDA. The tide has already turned. The American people know exactly what you are doing. We have the receipts. It will be relatively easy to secure a conviction at Nuremberg 2.0 — we literally have you on video committing crimes against humanity. As a reminder, the courts have determined that “I was just following orders” is not a valid defense.
After Summer, Europe to Target the Unvaccinated
BY ROBERT KOGON | BROWNSTONE INSTITUTE | MAY 28, 2022
Anyone who imagines that the suspension of Covid-related measures in much of Europe means that those measures, and hence the C-19 vaccination campaign, are things of the past should have a look at the recent pronouncements on the subject of the European Commission, starting with Commission President Ursula von der Leyen’s April 27 statement on the “next pandemic phase.”
While acknowledging that the “emergency” phase of the pandemic is over – but apparently not, on her account, the pandemic as such – von der Leyen warns that “we must remain vigilant. Infection numbers are still high in the EU and many people are still dying from COVID-19 worldwide. Moreover, new variants can emerge and spread fast.” “But we know the way forward,” she concluded, “We need to further step-up vaccination and boosting, and targeted testing”. The emphasis is mine.
Note that von der Leyen does not merely say that vaccination and boosting should continue – say perhaps for particularly vulnerable groups – she says rather that they have to be “further stepped-up”! This in an EU in which, according to the European Centre for Disease Prevention and Control, nearly 85% of the adult population has already been fully vaccinated!
In the Commission press release, von der Leyen’s call for “stepped-up” vaccination and boosting is the first of a series of measures that member states are called on to take “before autumn.”
A factsheet on “COVID-19 – Sustaining EU Preparedness and Response: Looking ahead,” which was published by the European Commission on the same day, April 27, reiterates von der Leyen’s point. The first section is entitled “Increasing uptake of COVID-19 vaccination” and the first bullet point reads:
• Member States should increase vaccination uptake and the administration of boosters and fourth doses for those who are eligible. They should also increase vaccination among children.
Here, the emphasis is in the original. The second bullet point continues:
• Member States should prepare COVID-19 vaccination strategies for the coming months taking into account the simultaneous circulation of seasonal influenza and incorporate COVID-19 vaccination into national vaccination programmes.
On May 12, The European Parliament’s recently created special committee on the Covid-19 pandemic (COVI) hosted a question-and-answer session with EU Health Commissioner Stella Kyriakides. (Full video here.) In a tweet, the French Member of the European Parliament Virginie Joron summed up the gist of Kyriakides’s remarks as follows (author’s translation):
PRIORITY: 100 million unvaccinated in EU who will have to be convinced and targeted without discriminating against them.
> combatting misinformation
> next pandemic with new variants this winter
Like Kyriakides, incidentally, the Commission press release also identifies “intensify[ing] collaboration against mis- and disinformation on COVID-19 vaccines” as one of the priority actions for the fall.
Finally, in a more recent May 17 tweet, Virginie Joron shared the below photo of a Commission document that was distributed to the EU Parliament’s Internal Market and Consumer Protection Committee and that includes, in effect, a “vaccination strategy” for the fall. This document likewise “targets” the unvaccinated, its first bullet calling on EU member states to: “Strengthen efforts to increase the uptake or completion of the primary course among the unvaccinated or partially vaccinated including by continuously monitoring and analysing vaccine hesitancy to overcome it.”

The emphasis on “targeting” the unvaccinated is particularly puzzling given how rapidly vaccine-induced protection against Covid-19 is now known to wane. In immunological terms, once it has, there is, of course, no meaningful distinction to be made anymore between vaccinated and unvaccinated. Some studies and data even suggest that the vaccinated are at this point more prone to infection. Only the very recently vaccinated may perhaps enjoy some added protection.
Numerous observational studies have demonstrated how rapidly the efficacy of the Covid-19 vaccines wanes: in particular, that of the BioNTech-Pfizer vaccine, which is by far the most widely-used vaccine in the EU. But there is no need to cite these studies here, since the very next bullet point in the Commission document tacitly acknowledges the rapid waning of vaccine efficacy, calling on member states to: “Increase efforts on the uptake of booster doses by all eligible adults, starting from three months after the primary course.” The emphasis here is again mine.
The third and last vaccine-related bullet-point specifically concerns child vaccination. It is truncated in the document photographed by Joron, but the full version is to be found in the Commission’s most complete statement of its Covid-19 strategy for the fall: a communication to the Parliament and other EU institutions that likewise dates from April 27. The full version of the recommendation reads as follows: “Before the beginning of the 2022-2023 school year, consider strategies to increase vaccination coverage rates among younger children, e.g. by working with paediatricians and other health professionals who are trusted sources of information for many parents.”
It was considerate of Kyriakides to insist that the unvaccinated should not be discriminated against, even if they need to be “targeted.” But it should be noted that the April 27 communication, as reflected in Joron’s photo, also stresses the need to “[e]nsure the adoption of the Commission proposal to extend the application of the EU Digital COVID Certificate Regulation.” The main effect and purpose of the EU Digital Covid Certificate, which has also served as framework and infrastructure for domestic “health” or “vaccine” certificates in EU member states, is, of course, precisely to reward the vaccinated and discriminate against the unvaccinated.
The European Commission’s April 27th documents thus clearly invoke a new rollout of the Covid-19 vaccination campaign in the fall, specifically targeting the hitherto unvaccinated and also children. Moreover, if the Commission gets its way – as it can be expected to – and the EU Digital Covid Certificate is indeed extended, they also raise the specter of this new rollout being combined with exactly the same coercive, discriminatory measures that turned Europe’s unvaccinated into social pariahs for much of the last year.
Robert Kogon is a pen name for a widely-published financial journalist, a translator, and researcher working in Europe. He writes at edv1694.substack.com.
DR. MCCULLOUGH ON MONKEYPOX
The Highwire with Del Bigtree | May 26, 2022
As the monkeypox outbreak saturates the news cycle, we check in with Epidemiologist and Cardiologist Dr. Peter McCullough to look into the danger the virus poses to the public.
Here’s what you should know about the latest Money Pox
Smallpox, money pox, and the vaccines they will try to frighten you into getting
By Meryl Nass, MD | May 27, 2022
The WHO released a clever statement to introduce the idea of mass money pox vaccination to the public:
The World Health Organization (WHO) maintains that the growing monkeypox outbreak remains “containable,” and that there’s no immediate need for mass vaccination against the orthopoxvirus; since May 7, a total of 131 confirmed cases and 106 suspected cases have been reported in countries where it usually does not spread. (Reuters)
No immediate need. Let that statement ferment in your unconscious. It seems like a benign sentence, but implicit in it is the idea that soon there may well be a need to mass vaccinate the population against money pox, a disease that has never before spread due to casual contact.
I don’t think we even know the actual mortality rate for money pox. Has a westerner ever died from it?
Could this possibly be the same money pox that occurs in Africa? If so, how did it suddenly appear in so many countries at once? This fact alone—its novel, never-before-seen pattern of spread, should make us question whether it is a biowarfare agent being seeded deliberately. Probably not meant to kill us, maybe not even to harm us much. We can’t tell yet, based on the minimalist info coming out of our esteemed public health agencies. Perhaps it’s here just to nudge us to get another shot?
Below I give you the basics on smallpox, monkeypox and the newest vaccines coming to a clinic near you:
1. If there is a money pox vaccine (and FDA has apparently approved one that the army helped develop) it has not been tested for efficacy, because there have not been enough human cases to do so.
- Efficacy testing requires that you vaccinate people and then see how many cases of the disease occur in the vaccinated versus the placebo group. If you were able to vaccinate a million people but disease frequency was such that you couldn’t even get a handful of cases occuring, you cannot perform an efficacy test.
- Instead, in order to get vaccines approved or authorized, antibody tests are done that are claimed to demonstrate the presence of immunity. But oft times (as in the COVID or anthrax vaccines) the antibody that is selected for this purpose may not be a reliable indicator of immunity…as admitted at the booster VRBPAC meeting by FDA staff and committee members.
2. The smallpox vaccine is said to be 85% effective against monkeypox… but without many human monkeypox cases, that 85% number cannot possibly have been established.
3. The smallpox vaccine causes a huge number of myocarditis cases and other known cardiac problems, making it almost certainly more dangerous than the risk of getting monkeypox. One in 220 recipients developed an obvious case of myocarditis in a US military study published in 2015, and one in 30 got a subclinical case.
Why would ANYONE take such a high risk of cardiac damage to avoid a miniscule risk of money pox? Only because they were misinformed.
4. Smallpox vaccine, when used routinely in babies, was considered the most dangerous vaccine available. It led to the deaths of several people per million administrations.
5. I received smallpox vaccines in 1951 and 1972 and believe I had insignificant reactions. I expect I am fully immune to smallpox. Tests done in people in 2003 published in NEJM suggested immunity was lifelong.
6. The US smallpox vaccine last used routinely in civilians was the NY Department of Health version, and it was made similarly to the vaccine of the 1700s. Infectious fluid from a related orthopox virus was scratched on the belly of a calf, and then when new vesicles developed the material was collected as the vaccine substrate, and could only be minimally purified.
7. Ever wonder why the smallpox vaccine is scratched on while all others are injected? Because it was so dirty, contaminated with other animal viruses and unspecified materials, which might cause a serious infection if injected beyond the skin.
8. It was hoped, 20-30 years ago, that a newer, cleaner, purified vaccine would avoid the many severe side effects. Two newer vaccines (ACAM 2000, purified from the NY DOH Dryvax vaccine and MVA) were purchased by the Clinton and Bush administrations for all Americans. It turned out, unfortunately, that the cardiac side effects persisted. They were due to the actual vaccine antigen, not to the ‘junk.’ The MVA (Modified Vaccinia Ankara) vaccine, which is less reactogenic but may be less effective than ACAM2000, had its US name changed to Jynneos, and has now been designated the official MoneyPox vaccine.
Regarding ACAM2000 and the licensing of Jynneos, FDA said in 2019 (on page 4):
ACAM2000 is contraindicated for use in individuals with severe immunodeficiency who are not expected to benefit from the vaccine… In 2003, a monkeypox
outbreak was confirmed in the U.S. This was the first time human monkeypox was
reported outside of the African continent. (Not true but close—Nass) Currently, there is no approved treatment
or licensed vaccine for monkeypox, although the Advisory Committee on
Immunization Practices (ACIP) recommends that ACAM2000 be used for prevention of monkeypox in individuals at high risk of exposure (e.g., lab workers who handle monkeypox virus). Thus, there is an unmet need for a monkeypox vaccine.
9. The US government initiated a smallpox vaccine program in 2003 that rapidly failed—people refused to be vaccinated due to high rates of heart attacks, heart failure and myocarditis. The National Academies of Science (NAS) wrote a series of about 8 critical “Letter Reports” on the government program, and the magazine Science wrote about the final report here. However, both the NAS and Science pulled their punches, failing the fully emphasize the dangers and to reflect the widespread skepticism about the program, which used a dangerous vaccine for a nonexistent or at least unproven threat.
10. According to Medpage, CDC says both Jynneos and ACAM2000 vaccines will be available to respond to the money pox event. Yet even CDC currently admits that the chance of myocarditis is huge (greater than one in 200 vaccine recipients) from the ACAM2000 vaccine, in an MMWR from November 2021:
Because ACAM2000 is replication-competent, there is a risk for serious adverse events (e.g., progressive vaccinia and eczema vaccinatum) with it; myopericarditis also occurs with ACAM2000 (estimated rate of 5.7 per 1,000 primary vaccinees based on clinical trial data), but the underlying mechanism is unknown (7,8).
11. From the same MMWR article , the CDC perhaps inadvertently admitted it had no reliable evidence for either safety or efficacy:
The effectiveness of JYNNEOS was inferred from the immunogenicity of JYNNEOS in clinical studies and from efficacy data from animal challenge studies. [But humans do not necessarily respond the same as lab animals—Nass] Occurrences of serious adverse events are expected to be minimal because JYNNEOS is a replication-deficient virus vaccine. However, because the mechanism for myopericarditis following receipt of ACAM2000 is thought to be an immune-mediated phenomenon, it is not known whether the antigen or antigens that precipitate autoantibodies [causing myocarditis or other adverse events—Nass] are present in JYNNEOS as well.
12. Despite knowing there is virtually no reliable information about how the vaccine might prevent monkeypox nor how safe it is, the Quebec government has begun rolling out the vaccine for the prevention of money pox. According to CBC:
… the smallpox vaccine — which hasn’t been routinely offered in Canada for decades — will be offered to those at high risk of contracting the disease, such as those who have been in contact with confirmed cases.
[Quebec’s top health officer] Boileau said the province has access to hundreds of doses at the ready, but vaccination will only occur after a recommendation from public health. It will not be open to the general public.
13. Whitney Webb wrote last week about two of the Beltway Bandits poised to make yet another killing on money pox, Emergent BioSolutions and SIGA Technologies.
I will be adding to this post.
As Questions Swirl Around Monkeypox Origins and Risk, Vaccine Makers Set Sights on Profits
By Michael Nevradakis, Ph.D. | The Defender | May 26, 2022
As an unprecedented outbreak of monkeypox spreads throughout the west, questions continue to swirl around the origin of the outbreak, the risk it poses to the public and the measures that may or may not be required to contain the virus.
Some also wondered how unexpected the outbreak was after learning about a March 2021 tabletop simulation of a hypothetical deadly outbreak of monkeypox predicted to occur in May 2022.
The Nuclear Threat Initiative and the Munich Security Conference — entities closely connected to the World Economic Forum (WEF), the Bill & Melinda Gates Foundation and the Johns Hopkins Center for Health Security — conducted the tabletop exercise.
Some analysts suggested the outbreak may have resulted from gain-of-function research or similar experiments involving the virus, while others floated the theory that malign actors, perhaps related to the conflict in Ukraine, intentionally released the virus.
Meanwhile, politicians and public health officials are delivering mixed and confusing messages to the public about the level of risk, while pharmaceutical companies are preparing to introduce monkeypox vaccines.
WHO responds with emergency meeting — just prior to its World Health Assembly
The World Health Organization (WHO) said it has considered monkeypox a “priority pathogen” for several years. Nevertheless, the new outbreak led the agency on May 20 to hold an emergency meeting of its Strategic and Technical Advisory Group on Infectious Hazards with Pandemic and Endemic Potential (STAG-IH) to discuss monkeypox.
STAG-IH, comprised of experts and scientists from around the world and chaired by David Heymann, professor of epidemiology at the London School of Hygiene and Tropical Medicine, advises the WHO on infection risks that could threaten global public health.
STAG-IH does not have the authority to declare a public health emergency of international concern — the WHO’s highest form of alert — which is currently active in relation to COVID-19.
The WHO convened the emergency meeting even though the organization was already set to meet for its World Health Assembly May 22-28 in Geneva, Switzerland — where members discussed proposed amendments to the existing International Health Regulations 2005, and where WHO Director-General Tedros Adhanom Ghebreyesus was re-elected without opposition to a second five-year term.
The WEF also held its annual meeting May 22-26 — in Davos, Switzerland, not far from Geneva.
Monkeypox response described as ‘gaslighting’
Health officials and politicians are responding to the sudden spread of monkeypox with mixed messages.
WHO Europe regional director Dr. Hans Kluge recently expressed concerns about transmission at “mass gatherings, festivals, and parties.”
President Biden also shared concerns, stating that “it is something that everybody should be concerned about … it is a concern in the sense that if it were to spread, it’s consequential.”
And the U.K.’s National Health Service issued an advisory recommending people “only eat meat that has been cooked thoroughly.”
However, other public health professionals said the risk to the public is low, as is the likelihood the epidemic will last very long.
In what has been described by scientist and author James Lyons-Weiler as an example of gaslighting, the Centers for Disease Control and Prevention (CDC) advised the public not to be concerned over the spread of monkeypox, contradicting President Biden’s warning.
An article in the Daily Mail delivered its own mixed messages by first warning, in capital letters, about a possible “hypermutated” monkeypox virus, then quoting Dr. Rosamund Lewis, who heads the smallpox secretariat on the WHO’s emergencies program, who said, “Despite suggestions that the virus may have evolved, experts have warned there is no evidence it has done so.”
Despite the fact that the WHO has not declared any kind of public health emergency related to the spread of monkeypox outside of Africa, various countries have begun enacting their own measures in response to the outbreak.
Public health authorities in Belgium announced May 20 that a compulsory 21-day quarantine will be imposed for monkeypox patients, U.K. health authorities urged “high risk” contacts of monkeypox cases to self-isolate and to avoid children for 21 days, and Greece and other countries are considering similar measures.
The Belgian Institute of Tropical Medicine announced it is conducting its own monkeypox PCR tests.
Smallpox outbreak: a new windfall for vaccine manufacturers and Big Pharma?
In response to the monkeypox outbreak, the Biden administration placed a $119 million order for smallpox vaccines from Bavarian Nordic, the manufacturer of JYNNEOS (also known as Imvamune and Imvanex), a smallpox vaccine also licensed to treat monkeypox.
The purchase includes a $180 million option for the purchase of future doses, bringing the combined total of the order to 13 million doses if the option is exercised.
According to Fortune :
“The order will convert existing smallpox vaccines, which are also effective against monkeypox, into freeze-dried versions, which have a longer shelf life. The converted vaccines will be manufactured in 2023 and 2024, the company says.
“Bavarian Nordic has worked with the U.S. government since 2003 to develop, manufacture and supply smallpox vaccines. To date, it says, it has supplied nearly 30 million doses to the Department of Health and Human Services.”
The U.K. ordered more than 20,000 doses of JYNNEOS, while the European Centre for Disease Prevention and Control reportedly is set to recommend a monkeypox vaccine plan for EU member states.
Existing smallpox vaccines reportedly are up to 85% effective against monkeypox. With the recent outbreak, health authorities in countries such as the U.K. have begun administering the smallpox vaccine to healthcare workers and others who may have been exposed to monkeypox.
The U.S. Food and Drug Administration (FDA) in 2019 approved the JYNNEOS smallpox vaccine, which was developed in conjunction with U.S. Army scientists.
After JYNNEOS received FDA approval, Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said:
“[A]lthough naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect.
“Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection.
“This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted.”
Dr. Anthony Fauci had a hand in the development of JYNNEOS, with accompanying controversy, as highlighted in 2009:
“Fauci gave about $100 million each to Bavarian Nordic and Acambis for research on a smallpox vaccine in preparation for a BioShield contract to be awarded in 2006.
“Some observers have said that Fauci is ‘overstepping his bounds,’ [The Wall Street] Journal reports.”
A study published in February 2022 in the PLOS Neglected Tropical Diseases journal, “initiated and funded by Bavarian Nordic” and co-authored by employees of the company, states:
“The appearance of outbreaks beyond Africa highlights the global relevance of the disease.
“Increased surveillance and detection of monkeypox cases are essential tools for understanding the continuously changing epidemiology of this resurging disease.
“Overall, monkeypox is gradually evolving to become of global relevance.”
Bavarian Nordic isn’t the only drugmaker focused on monkeypox. On May 19, the FDA approved an additional drug, an intravenous version of TPOXX (tecovirimat) for the treatment of monkeypox.
TPOXX is produced by SIGA, described by Bloomberg as “a biological warfare defense firm.”
According to SIGA, “Funding and technical support for this work is provided by the Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS).”
As reported by The Gateway Pundit :
“TPOXX has been available for use to treat smallpox for several years, but it was only available in pill form.
“The new version of TPOXX will be delivered directly into the bloodstream via injection and also reportedly works for treating monkeypox.”
The previous oral formulation of TPOXX was approved by the FDA in July 2018. That same year, SIGA signed a $629 million contract with BARDA for the inclusion of smallpox drugs in the Strategic National Stockpile.
SIGA reached a similar agreement with Canadian authorities in December 2021, less than a month after Bill Gates warned of the risk of a bioterror attack.
In June 2019, SIGA signed an international promotion agreement with Meridian Medical Technologies, a company owned by Pfizer.
Recent developments sent the stocks of SIGA and Bavarian Nordic soaring. SIGA’s stock, which previously peaked in November 2021, rose soon after Gates’ pronouncements regarding the possibility of an intentional release of smallpox.
In a recent article, investigative journalist Whitney Webb highlighted the potentially troubling track record of SIGA and another smallpox vaccine manufacturer, Emergent Biosolutions, including:
- Close ties to Jeffrey Epstein and the Democratic Party.
- “Outrageous” no-bid federal contracts to SIGA for the procurement of smallpox drugs.
- “Troubling ties” to the 2001 anthrax attacks.
- “Serious deficiencies” at a manufacturing plant of a smallpox vaccine producer, Emergent Biosolutions, that also produced COVID-19 vaccines.
Webb also discovered a direct link between Emergent Biosolutions, the Strategic National Stockpile, the anthrax attacks of 2001, the Dark Winter simulation and Bavarian Nordic — via Robert Kadlec, who served as the top bioterror advisor to the Pentagon in the weeks leading up to the 2001 anthrax attacks.
Kadlec participated in the June 2001 Dark Winter simulation of an anthrax attack, helped establish the Strategic National Stockpile, and has directly advised Emergent Biosolutions and Bavarian Nordic.
New players also are jostling for position in light of the monkeypox outbreak, including a familiar face: COVID-19 vaccine manufacturer Moderna, which recently announced it is testing potential monkeypox vaccines.
Confusion over who — or what — to blame for the monkeypox outbreak
Analyst Paul Craig Roberts recently wrote, “No one has explained why and how monkeypox, a problem in a small area of Africa, suddenly appeared all at once all over the Western world,” asking if we are about to experience another fear campaign, or something even worse.
The questions posited by Roberts point to the broader confusion, at least from what is evident through publicly available information, as to the origin of the monkeypox outbreak and how it is spreading.
Many scientists reportedly are “baffled” by the “unprecedented” spread of monkeypox outside of Africa and find its spread in North America and Europe to be “perplexing.”
This may remind some of the spread of the Omicron variant of COVID-19, which was said to have emerged in Botswana and South Africa without, apparently, heavily impacting those countries.
Oyewale Tomori, a virologist and former president of the Nigerian Academy of Science who currently serves on various WHO advisory committees, was quoted as saying:
“I’m stunned by this. Every day I wake up and there are more countries infected … [t]his is not the kind of spread we’ve seen in West Africa, so there may be something new happening in the West.”
Dr. Hans Kluge, the WHO’s Europe director, characterized the situation as “atypical.”
“We’ve never seen anything like what’s happening in Europe,” said Christian Happi, director of the African Centre of Excellence for Genomics of Infectious Diseases.
Happi also suggested the cessation of smallpox vaccination campaigns in 1980, when the disease was declared eradicated, may be contributing to the spread of monkeypox, as no immunity against smallpox or monkeypox would exist in the population.
This view was mirrored recently in an analysis by Jason Gale of Bloomberg, and picked up by the Washington Post. Gale argued that the eradication of smallpox “led to the end of a global vaccination program that provided protection against other poxviruses [including] monkeypox.”
Others argued the low level of incidence of smallpox makes vaccination against it more of a risk than a benefit.
Debates appear to be ongoing in the scientific community as to whether monkeypox is now being sexually transmitted.
Tomori noted sexual transmission has not been observed in Nigeria, but also that viruses not previously known to transmit via sexual contact, such as Ebola, were later proven to do so.
Alessio D’Amato, health commissioner of the Lazio region in Italy, said it was too early to say if monkeypox has morphed into a sexually transmitted disease, while Stuart Neil, professor of virology at King’s College London, said, “The idea that there’s some sort of sexual transmission in this, I think, is a little bit of a stretch.”
Neil Mabbott, personal chair of immunopathology at the University of Edinburgh’s Roslin Institute, argued the spread of monkeypox among sexual partners is likely due to close physical proximity rather than sexual contact per se.
However, David Heymann, an infectious disease specialist at the WHO who led the organization’s recent emergency meeting on monkeypox, suggested the virus entered the population as a “sexual form, as a genital form, and is being spread as are sexually transmitted infections.”
This appears to be aligned with the WHO’s current official view that sexual contact is responsible for the spread of monkeypox, not as a sexually transmitted disease but by virtue of close physical contact.
Is the current monkeypox outbreak related to gain-of-function research?
The term “gain-of-function” (GoF) research over the past two years entered mainstream discourse following speculation the SARS-CoV-2 virus was engineered, and subsequently escaped from, the Wuhan Institute of Virology in Wuhan, China.
GoF refers to medical research in which an organism is genetically altered, either for military purposes or medical research, in such a way that the biological functions of gene products are enhanced.
The National Pulse reported that in February 2022, Virologica Sinica, a prominent journal of virology, published a peer-reviewed study pertaining to a monkeypox-related GoF research project performed by scientists at the Wuhan Institute of Virology in August 2021.
In this study, according to The National Pulse :
“The Wuhan Institute of Virology assembled a monkeypox virus genome, allowing the virus to be identified through PCR tests, using a method researchers flagged for potentially creating a ‘contagious pathogen.’
“The paper … also follows the wide-scale use of Polymerase Chain Reaction (PCR) tests to identify COVID-19-positive individuals.
“Researchers appeared to identify a portion of the monkeypox virus genome, enabling PCR tests to identify the virus.”
Canadian researcher Polly St. George in a recent investigative report said there is an association between monkeypox and GoF research.
And in a recent interview, international law scholar Francis Boyle, who drafted the Biological Weapon Anti-Terrorism Act of 1989, said the bioware industry uses monkeypox as a simulant for smallpox.
Along these lines, geopolitical analyst Michael Whitney in a recent article remarked on the sudden rapid spread of monkeypox and posed the following question:
“I wonder if that ‘rapidly spreading’ part has something to do with the way that researchers have been tweaking the gain-of-function of these unique pathogens in order to make them more contagious and more lethal? Is that what’s going on?”
Similarly, James Lyons-Weiler pointed out monkeypox first officially appeared in 1958, “about the time scientists were injecting African subjects with blood products from monkeys to see which viruses might be transmissible. Zikavirus came into our species about the same time.”
Uncertainty breeds speculation, and such is the case with some who suggested a possible link between the monkeypox outbreak and a January 2022 incident involving a truck transporting 100 laboratory monkeys that collided with a dump truck and overturned in Pennsylvania, leading to the escape of at least three monkeys.
The monkeys reportedly were later caught and euthanized, though no reason was given as to why they were killed.
An eyewitness who handled escaped monkeys developed pink eye and a cough, received treatment and was monitored by the CDC.
Others also tried to draw a connection between monkeypox and the AstraZeneca COVID-19 vaccine, which utilizes a chimpanzee adenovirus vaccine vector.
However, no such link has been reported, and it’s important to note that chimpanzees are distinct from monkeys.
Is monkeypox outbreak a tool of intentional warfare?
Some officials speculated monkeypox was weaponized and intentionally released as an act of biological warfare, perhaps in relation to the conflict in Ukraine.
There are at least three such strands of speculation currently circulating:
- Claims by independent investigator Dr. Benjamin Braddock that an unnamed source at the European Centre for Disease Prevention and Control said, “Preliminary analysis of the monkeypox strain currently doing the rounds found the virus came from a lab and may be related to the U.S.’s biological research in Ukraine,” implying that it may have been intentionally released, perhaps by Russia.
- Theories circulating in China and reported by Chinese state media that the U.S. intentionally released the virus, as part of “a plan by the U.S. to leak bioengineered monkeypox virus.”
- Statements by Irina Yarovaya, co-chair of Russia’s parliamentary commission on investigation of U.S. biological laboratories in Ukraine, and reported by Russia’s TASS news agency, that “the U.S. researched Ebola and smallpox viruses in Ukraine,” perhaps implying this resulted in the monkeypox outbreak.
These scenarios remain within the realm of speculation for the time being, but bear a close resemblance to the Wuhan lab leak scenarios under investigation in relation to the outbreak of COVID-19.
However, even if none of these scenarios hold water, they possess evident value as tools of information warfare, especially in relation to the ongoing schism between Russia and the West vis-à-vis the conflict in Ukraine.
Are monkeypox symptoms similar to COVID vaccine side effects?
Despite the current scare, monkeypox symptoms for most individuals who have been infected are mild, particularly in countries with adequate health systems.
However, they also resemble known adverse effects of the COVID-19 vaccines and symptoms of ailments such as shingles.
According to the WHO, monkeypox symptoms are characterized by “a person of any age presenting in a monkeypox non-endemic country with an unexplained acute rash,” with one or more of the following symptoms (updated March 15, 2022):
- Headache
- Acute onset of fever (>38.5oC)
- Lymphadenopathy (swollen lymph nodes)
- Myalgia (muscle and body aches)
- Back pain
- Asthenia (profound weakness)
Notably, many of these symptoms appear in the list of adverse effects of the Pfizer COVID-19 vaccine. These adverse effects include lymphadenopathy, myalgia, asthenia, back pain and headache.
Others noted the similarity between monkeypox and shingles. Indeed, an image published by TheHealthSite.com of rashes said to be caused by smallpox is identical to an image published by Australia’s Queensland government displaying shingles rashes.
The CDC states, “The rash may be hard to distinguish from syphilis, herpes simplex virus infection, shingles and other more common infections.”
Moreover, according to Andrew Preston, professor of microbial pathogenicity at the University of Bath, “Some people say the rash is a bit like shingles.”
In recent years, certain countries, such as the U.K., have introduced a comprehensive shingles vaccination campaign for individuals age 70 and over.
Michael Nevradakis, Ph.D., is an independent journalist and researcher based in Athens, Greece.
Climate madness: British startup releases masks for cows
British startup ZELP has developed a mask for cows that filters methane. They received a climate protection award for this – Prince Charles is thrilled about the project.

Free West Media | May 28, 2022
It sounds like a belated April Fool’s joke: On May 24, 2022, the online portal Agrarheute reported that the British startup ZELP (Zero Emissions Livestock Project) had developed masks for cows. In this case, however, not to protect them from Corona, but to filter methane.
ZELP is currently testing various prototypes of the cattle masks, according to Agrarheute. These are already able to filter around 30 percent of the methane emitted by ruminants. In the future, this value should be increased to around 60 percent.
The highlight: ZELP was awarded the climate protection prize “Climate Design Award” for the “revolutionary” idea, which was created by WEF figurehead Prince Charles and designer Sir Jony Ive. The cattle mask was one of four winners and received a cash prize of the equivalent of 58 000 euros. Prince Charles supports face masks for cows to fight climate change.
The British monarch is one of the architects of the Great Reset, the name of the 50th annual meeting of the World Economic Forum (WEF), held in June 2020. It brought together high-profile business and political leaders, convened by Prince Charles. At the launch event for the Great Reset, he listed key areas for action, similar to those listed in his Sustainable Markets Initiative. These included draconian measures for net zero emissions globally as well as the introduction of carbon pricing.
To prove that this report was not a joke, the portal linked a video in its article that showed the enthusiastic heir to the throne presenting the project.
The 100-gram rubber masks with solar-powered fans are designed to direct the animals’ exhalations into a small chamber and then use chemical processes to convert methane into carbon dioxide, Agrarheute explained. But first farmers have to be convinced to actually use the masks.
One obstacle could be the rather high price: The use costs 45 dollars per cow and year, the equivalent of 41 euros. In addition, the masks would not bring any advantage for the farmer from an economic point of view.
In the comments below the article, readers legitimately wondered whether this message was some kind of joke. Agrarheute immediately confirmed that this was unfortunately not the case.
The claims about methane have been debunked
One reader commented: “Madness or stupidity? Every thinking person understands what nonsense the story about cow’s methane is. A cow is not a perpetual motion machine and it does not create energy out of thin air. The cow lives in the earth’s natural carbon cycle and is not ‘climate-damaging’ (if such a thing exists). Even the climate heroes at Climate Facts know that, although some people don’t like it. They are just producing a lot of garbage, trying to get more money out of the farmers’ pockets, end of the story.”
The three main greenhouse gases, carbon dioxide, methane and nitrous oxide, all impact the environment differently. Methane is known as a “flow gas”, removed from the atmosphere at a rapid pace. Methane’s lifespan in the atmosphere is approximately 10 years, but flow gases will stay stagnant as they are destroyed at the same rate of emission.
Thus the initial method for calculating greenhouse emissions misrepresents the impact of short-lived flow gases, like methane, on future warming.
The hypocrisy of the global elite
The global elite pushing the Great Reset this week emitted thousands of units of carbon dioxide with an estimated lifespan in the atmosphere of 1000 years, meaning carbon dioxide emitted from the year 2022 will still be in the atmosphere in 3022. Meeting via Zoom for example, would have been a much better choice, given their “concerns” about climate change.
Traveling in private jets to the Davos Summit in Switzerland to foist their climate agenda on the rest of the world to “limit global temperature rise and stave off disaster” as stated on its website, “10 private one-way flights departed various European cities on Wednesday evening and landed in St. Gallen-Altenrhein Airport, the closest airstrip to Davos, emitting approximately 43 440 pounds of carbon dioxide into the atmosphere”.
For the WEF annual meeting in 2019 in Davos, according to an analysis from Air Charter Service, The Guardian reported at the time that around 1 500 private jets flew to and from airports near the Swiss town.








